Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410
Debt
Debt-to-Equity RatioN/A
Current Ratio9.56
Quick Ratio9.56
Price-To-Earnings
Trailing P/E Ratio-18.47
Forward P/E Ratio-19.23
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.31 per share
Price / Book9.67
Profitability
EPS (Most Recent Fiscal Year)($2.78)
Net Income$-70,420,000.00
Net MarginsN/A
Return on Equity-62.28%
Return on Assets-55.07%
Miscellaneous
Employees51
Outstanding Shares29,050,000
Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions
What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."
How were Mirati Therapeutics' earnings last quarter?
Mirati Therapeutics Inc (NASDAQ:MRTX) posted its earnings results on Monday, May, 7th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.12. The biotechnology company earned $9.47 million during the quarter, compared to analyst estimates of $10 million. View Mirati Therapeutics' Earnings History.
What price target have analysts set for MRTX?
10 equities research analysts have issued 1 year target prices for Mirati Therapeutics' stock. Their predictions range from $5.00 to $60.00. On average, they expect Mirati Therapeutics' share price to reach $27.6667 in the next twelve months. View Analyst Ratings for Mirati Therapeutics.
What are Wall Street analysts saying about Mirati Therapeutics stock?
Here are some recent quotes from research analysts about Mirati Therapeutics stock:
- 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (5/9/2018)
- 2. Cann analysts commented, "Mirati Therapeutics, Inc. announced today that it has entered into an exclusive license agreement with BeiGene for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati confirmed it will retain exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world." (1/8/2018)
Who are some of Mirati Therapeutics' key competitors?
Some companies that are related to Mirati Therapeutics include Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO), FibroGen (FGEN), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL) and HUTCHISON CHINA/S (HCM).
Who are Mirati Therapeutics' key executives?
Mirati Therapeutics' management team includes the folowing people:
- Dr. Rodney W. Lappe, Exec. Chairman (Age 63)
- Dr. Charles M. Baum, Pres, CEO & Director (Age 60)
- Dr. James Christensen, Sr. VP & Chief Scientific Officer (Age 50)
- Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 56)
- Mr. Jamie A. Donadio, Sr. VP & CFO (Age 43)
Has Mirati Therapeutics been receiving favorable news coverage?
Media headlines about MRTX stock have trended positive on Saturday, according to Accern. The research firm ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.26 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.04 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Mirati Therapeutics' major shareholders?
Mirati Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.19%), Point72 Asset Management L.P. (1.40%), PointState Capital LP (1.03%), Farallon Capital Management LLC (0.93%), Rock Springs Capital Management LP (0.65%) and Acuta Capital Partners LLC (0.34%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Jamie A Donadio, Jamie Christensen, Ltd Braslyn, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.
Which institutional investors are selling Mirati Therapeutics stock?
MRTX stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Citigroup Inc. and Federated Investors Inc. PA. Company insiders that have sold Mirati Therapeutics company stock in the last year include Jamie A Donadio, Jamie Christensen and Tuesday Thirteen Inc. View Insider Buying and Selling for Mirati Therapeutics.
Which institutional investors are buying Mirati Therapeutics stock?
MRTX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., PointState Capital LP, Farallon Capital Management LLC, BlackRock Inc., Tibra Equities Europe Ltd, Iguana Healthcare Management LLC, EAM Global Investors LLC and UBS Group AG. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Ltd Braslyn and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.
How do I buy shares of Mirati Therapeutics?
Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mirati Therapeutics' stock price today?
One share of MRTX stock can currently be purchased for approximately $51.35.
How big of a company is Mirati Therapeutics?
Mirati Therapeutics has a market capitalization of $1.52 billion. The biotechnology company earns $-70,420,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Mirati Therapeutics employs 51 workers across the globe.
How can I contact Mirati Therapeutics?
Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]
MarketBeat Community Rating for Mirati Therapeutics (MRTX)
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
